Stiff-Person Syndrome
9
1
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
11.1%
1 terminated out of 9 trials
66.7%
-19.8% vs benchmark
11%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
Evaluating Spinal Cord Stimulation for Stiff Person Syndrome
KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome
Efgartigimod for Stiff Person Syndrome (ESPS)
Biomarkers in Autoimmune Disease of Nervous System
Stem Cell Transplantation for Stiff Person Syndrome (SPS)
HLA Analysis in Autoimmune Encephalitis and Related Disorders
Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome
Efficacy and Mechanism of Action of SCIg in Patients With Stiff Person Syndrome (SPS)
Cause, Development, and Progression of Stiff-Person Syndrome